$6,599.00
Picray in combination with fulvestrant is indicated for the treatment of postmenopausal women and men with hormone receptor positive (HR+), human epidermal growth factor receptor type 2 (HER2-) negative advanced or metastatic PIK3CA (PIK3CA+) mutated breast cancer. ) with disease progression during/after endocrine therapy regimens.
Active ingredient: alpesinib
Prescription medicine.
| Дозировка | 150 Mg, 200 Mg |
|---|
